Aktob

Ingredient matches for Aktob

Tobramycin

Tobramycin is reported as an ingredient of Aktob in the following countries:

• United States

International Drug Name Search

Ungel

Ungel may be available in the countries listed below.

Ingredient matches for Ungel

Triclocarban

Triclocarban is reported as an ingredient of Ungel in the following countries:

• Argentina

International Drug Name Search

Afinitor

Afinitor is a brand name of everolimus, approved by the FDA in the following formulation(s):

AFINITOR (everolimus - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: March 30, 2009
  
  Strength(s): 10MG ^[RLD], 5MG
  


• 
  Manufacturer: NOVARTIS
  
  Approval date: July 9, 2010
  
  Strength(s): 2.5MG
  

Has a generic version of Afinitor been approved?

No. There is currently no therapeutically equivalent version of Afinitor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Afinitor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
  Patent 5,665,772
  Issued: September 9, 1997
  Inventor(s): Cottens; Sylvain & Sedrani; Richard
  Assignee(s): Sandoz Ltd.
  Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
  
  Patent expiration dates:
  
  
  • September 9, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 9, 2019
    
  
  



• 
  Pharmaceutical compositions comprising rafamycin coprecipitates
  Patent 6,004,973
  Issued: December 21, 1999
  Inventor(s): Guitard; Patrice & Haeberlin; Barbara & Link; Rainer & Richter; Friedrich
  Assignee(s): Novartis AG
  Disclosed are pharmaceutical compositions containing solid dispersions in the form of co-precipitates, which solid dispersions contain rapamycin and a carrier medium, and methods of treatment utilizing such pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • July 12, 2016
    
    ✓ 
    Drug product
  
  



• 
  Macrolides
  Patent 7,297,703
  Issued: November 20, 2007
  Inventor(s): Navarro; Francois & Petit; Samuel & Stone; Guy
  Assignee(s): Novartis AG
  A mixture comprising a poly-ene macrolide and an antioxidant. Preferably, the poly-ene macrolide is rapamycin and the antioxidant is 2, 6-di-tert.-butyl-4-methylphenol. The presence of the antioxidant improves the stability of the poly-ene macrolide to oxidation.
  
  Patent expiration dates:
  
  
  • December 6, 2019
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 29, 2013 - TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
  
  
  • March 30, 2014 - NEW CHEMICAL ENTITY
  
  
  • May 5, 2014 - FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
  
  
  • October 29, 2017 - ORPHAN DRUG EXCLUSIVITY
  
  
  • May 5, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Afinitor Consumer Information (Drugs.com)
• Afinitor Consumer Information (Wolters Kluwer)
• Afinitor Consumer Information (Cerner Multum)
• Afinitor Advanced Consumer Information (Micromedex)
• Afinitor AHFS DI Monographs (ASHP)
• Everolimus Consumer Information (Wolters Kluwer)
• Everolimus Consumer Information (Cerner Multum)
• Everolimus Advanced Consumer Information (Micromedex)
• Everolimus AHFS DI Monographs (ASHP)

Arkin-Z

Arkin-Z may be available in the countries listed below.

Ingredient matches for Arkin-Z

Vesnarinone

Vesnarinone is reported as an ingredient of Arkin-Z in the following countries:

• Japan

International Drug Name Search

Diclofenac K APR

Diclofenac K APR may be available in the countries listed below.

Ingredient matches for Diclofenac K APR

Diclofenac

Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Diclofenac K APR in the following countries:

• Switzerland

International Drug Name Search

Humex conjonctivité allergique

Humex conjonctivité allergique may be available in the countries listed below.

Ingredient matches for Humex conjonctivité allergique

Cromoglicic Acid

Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Humex conjonctivité allergique in the following countries:

• France

International Drug Name Search

Renal Caps

acid, thiamine mononitrate, riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, biotin and calcium pantothenate

Dosage Form: capsule, liquid filled
Renal Caps

Description

Renal Caps are opaque black oval softgels imprinted "C 162".  These softgels provide water-soluble vitamins.  Renal Caps contain the following inactive ingredients: Blue 1 Lake, gelatin, glycerin, lecithin, Red 40 Lake, soybean oil, starch, titanium dioxide, Yellow # 6 Lake, yellow beeswax.

Each softgel contains:

Vitamin C (ascorbic acid)........................100 mg

Thiamine (as thiamine mononitrate)..........1.5 mg

Riboflavin...............................................1.7 mg

Niacin (as niacinamide).............................20 mg

Vitamin B6 (as pyridoxine HCl)...................10 mg

Folate (folic acid).........................................1mg

Vitamin B12 (as cyanocobalamin)...............6 mcg

Biotin....................................................150 mcg

Pantothenic Acid (as calcium pantothenate)..5 mg

Indications and Usage

Renal Caps is indicated in the wasting syndrome of chronic renal failure; uremia and impaired metabolic functions of the kidney.  Renal Caps ia also highly effective as a stress vitamin.

Precautions

Folic acid may mask the symptoms of pernicious anemia in that hematologic remission may occur while neurological manifestations progress.

Dosage and Administration

One softgel daily, or as directed by physician.  If on dialysis, take after treatment.

Storage

Store at controlled room temperature 15-30o C (59-86oF).  Keep container tightly closed and protected from heat and moisture.

KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.

Manufactured for Cypress Pharmaceutical, Inc.

Madison, MS  39110

L404 Rev 6/02

NDC 60258-162-01

Renal Caps

Dialysis/ Stress

Vitamin Supplement

Rx Only

Cypress Pharmaceutical, Inc.

100 Softgels

Renal Caps  DIALYSIS/STRESS VITAMIN SUPPLEMENT ascorbic acid, thiamine mononitrate,riboflavin, niacinamide, pyridoxine hydrochloride, folic acid, cyanocobalamin, biotin, calcium pantothenate,   capsule, liquid filled

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 60258-162 Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength ASCORBIC ACID (ASCORBIC ACID) ASCORBIC ACID 100 mg THIAMINE MONONITRATE (THIAMINE ) THIAMINE MONONITRATE 1.5 mg RIBOFLAVIN (RIBOFLAVIN) RIBOFLAVIN 1.7 mg NIACINAMIDE (NIACINAMIDE) NIACINAMIDE 20 mg PYRIDOXINE HYDROCHLORIDE (PYRIDOXINE) PYRIDOXINE HYDROCHLORIDE 10 mg FOLIC ACID (FOLIC ACID) FOLIC ACID 1 mg CYANOCOBALAMIN (CYANOCOBALAMIN) CYANOCOBALAMIN 6000 ug BIOTIN (BIOTIN) BIOTIN 150000 ug CALCIUM PANTOTHENATE (CALCIUM PANTOTHENATE) CALCIUM PANTOTHENATE 5 mg

Inactive Ingredients Ingredient Name Strength No Inactive Ingredients Found

Product Characteristics Color black (C;162) Score no score Shape CAPSULE Size 15mm Flavor Imprint Code C;162 Contains

Packaging # NDC Package Description Multilevel Packaging 1 60258-162-01 100 CAPSULE In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved other		10/31/2002

Labeler - Cypress Pharmaceutical, Inc. (790248942)

Registrant - Cypress Pharmaceutical, Inc. (790248942)

Establishment
Name	Address	ID/FEI	Operations
Accucaps Industries Limited		248441727	manufacture

Revised: 10/2009Cypress Pharmaceutical, Inc.

More Renal Caps resources

• Renal Caps Use in Pregnancy & Breastfeeding
• Renal Caps Drug Interactions
• Renal Caps Support Group
• 0 Reviews for Renal Caps - Add your own review/rating

• multivitamin Concise Consumer Information (Cerner Multum)


• Multivitamin Drops MedFacts Consumer Leaflet (Wolters Kluwer)


• Balanced B-50 Controlled-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)


• Cardiotek-RX MedFacts Consumer Leaflet (Wolters Kluwer)


• Cerefolin MedFacts Consumer Leaflet (Wolters Kluwer)


• Cholinoid MedFacts Consumer Leaflet (Wolters Kluwer)


• Diatx MedFacts Consumer Leaflet (Wolters Kluwer)


• Folbee Plus MedFacts Consumer Leaflet (Wolters Kluwer)


• Folcaps MedFacts Consumer Leaflet (Wolters Kluwer)


• Foltrate MedFacts Consumer Leaflet (Wolters Kluwer)


• Ivites Rx MedFacts Consumer Leaflet (Wolters Kluwer)


• Metanx MedFacts Consumer Leaflet (Wolters Kluwer)


• Nephrocaps


• Protegra MedFacts Consumer Leaflet (Wolters Kluwer)


• Tri-Vi-Sol MedFacts Consumer Leaflet (Wolters Kluwer)


• Vitamin A Monograph (AHFS DI)

Compare Renal Caps with other medications

• Dietary Supplementation
• Hyperhomocysteinemia